Janux Therapeutics, Inc. (NASDAQ:JANX) Holdings Lifted by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 41.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,008 shares of the company’s stock after acquiring an additional 11,085 shares during the quarter. Rhumbline Advisers owned about 0.07% of Janux Therapeutics worth $1,592,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JANX. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics during the 2nd quarter valued at $29,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics during the second quarter valued at $151,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 82.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after purchasing an additional 4,400 shares during the last quarter. DNB Asset Management AS acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at $221,000. Finally, Principal Financial Group Inc. purchased a new position in Janux Therapeutics in the 2nd quarter worth about $237,000. 75.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on JANX shares. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Scotiabank reduced their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Wedbush reiterated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Janux Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Janux Therapeutics Stock Performance

Shares of JANX opened at $50.20 on Friday. The firm has a market cap of $2.60 billion, a PE ratio of -41.15 and a beta of 3.57. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $65.60. The firm’s 50 day moving average price is $43.43 and its 200 day moving average price is $44.23.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The business had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business’s revenue was up 709.1% on a year-over-year basis. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 268,578 shares of company stock valued at $12,071,151 over the last quarter. Insiders own 35.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.